Also trades as: 0JBU.L (LSE) · $vol 0M
NTLA NASDAQ
Intellia Therapeutics, Inc.
1W: -5.5%
1M: -25.4%
3M: -2.1%
YTD: +34.3%
1Y: +27.9%
3Y: -71.7%
5Y: -81.5%
$12.60
+0.23 (+1.86%)
After Hours: $12.52 (-0.08, -0.60%)
Weekly Expected Move ±12.4%
$10
$12
$14
$15
$17
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Intellia Therapeutics to Participate in Upcoming Investor Conferences
Cathie Wood's Ark bets on Google, Meta and CoreWeave; cuts AMD and Bitcoin ETF
Cathie Wood Buys Tumbling Robinhood Stock, ARK Adds $30 Mil Of This Stock
ARK Investment Acquires 2.4 Million Shares of Intellia Therapeutics (NTLA) - GuruFocus
Dow, S&P 500, Nasdaq futures slide as US-Iran talks hit roadblock: Why AMD, POET, ATOM, NTLA stocks are in focus - MSN
NTLA Stock Slides As $150M Offering Signals Dilution Risk - timothysykes.com
KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
NTLA Secures $180 Million in Increased Common Stock Offering - GuruFocus
NTLA Stock Pressured As $150M Offering Tests Trader Nerves - StocksToTrade
Cathie Wood Loads Up $14 Million on Alphabet Just Before Earnings
Intellia Therapeutics prices $180M stock offering at discount
NTLA stock surges 35% overnight: Retail mood peaks ahead of first-ever phase 3 readout for gene-editing therapy - MSN
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Robinhood Posts Downbeat Q1 Results, Joins Enphase Energy, Avis Budget And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock - Intellia Therapeutics
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
Why Intellia Therapeutics (NTLA) Is Down 13.8% After Positive Phase 3 HAE Gene-Editing Results And FDA Filing - simplywall.st
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt - Seeking Alpha
Intellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA Filing
Intellia Therapeutics Inc (NTLA) Stock Price, Trades & News - GuruFocus
Why The Narrative Around Intellia Therapeutics (NTLA) Is Shifting After FDA Hold Resolutions
Intellia Successfully Edited Genes Inside The Body. Why Shares Aren't Flying.
Intellia Successfully Edited Genes Inside The Body. Why Shares Aren't Flying. - Investor's Business Daily
Intellia Announces Proposed Public Offering of Common Stock
Intellia Announces Proposed Public Offering of Common Stock
Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy?
Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy? - Barchart.com
Intellia Stock Jumps 25%. A Key Trial Is Driving the Rally
Intellia Therapeutics Shares Slip Despite Strong Phase 3 Data
Intellia seeks FDA approval for in vivo CRISPR therapy
Intellia Therapeutics FDA Rolling Application For Gene Therapy Puts Hype To Test
Intellia Therapeutics Stock (NTLA) Opinions on Phase 3 HAE Trial Results - Quiver Quantitative
3 Biotech Stocks That Could Benefit from the Patent Cliff
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Biggest stock movers Monday: OGN, QCOM, and more
Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder
3 Biotech Stocks That Could Benefit from the Patent Cliff
NTLA stock rockets after hours before critical data for genetic disorder therapy - MSN
SA analyst downgrades: PLTR, PSTG, NTLA, ARWR - MSN
NTLA stock rises 20% in 3 months: Here's what you should know - MSN
NTLA stock rockets after hours before critical data for genetic disorder therapy - MSN
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits
NTLA Stock Rockets After Hours Before Critical Data For Genetic Disorder Therapy - Stocktwits
Intellia Therapeutics (NTLA) Set to Release Phase 3 Data for Her - GuruFocus
12 Health Care Stocks Moving In Friday's After-Market Session
First Phase 3 readout for an in-body CRISPR treatment arrives Monday - Stock Titan
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026
$NTLA stock is down 9% today. Here's what we see in our data. - Quiver Quantitative
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.6% - Should You Sell? - MarketBeat
ARK Investment buys 560K shares of Intellia Therapeutics - MSN
ARK Investment buys 560K shares of Intellia Therapeutics - MSN
NTLA stock rises 20% in 3 months: Here's what you should know - MSN
Intellia Therapeutics (NTLA) Sector Trends | Q4 2025: Profit Surprises - Trending Momentum Stocks - Cổng thông tin điện tử Tỉnh Sơn La
(NTLA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Intellia Therapeutics, Inc. (NTLA) Sees Moderate Buy Rating From Analysts - Insider Monkey
Intellia Therapeutics, Inc. (NTLA) Sees Moderate Buy Rating From Analysts - Yahoo Finance
Intellia Therapeutics, Inc. (NTLA) Sees Moderate Buy Rating From Analysts
NTLA stock rises 20% in 3 months: Here's what you should know - MSN
Massachusetts Financial Services Co. MA Makes New $318,000 Investment in Intellia Therapeutics, Inc. $NTLA
Most shorted small cap stocks as of mid-April led by healthcare sector
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know - Yahoo Finance
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know
2 Healthcare Stocks to Buy and 1 to Approach With Caution
2 Healthcare Stocks to Buy and 1 to Approach With Caution
How The Narrative On Intellia Therapeutics (NTLA) Is Shifting After MAGNITUDE Hold Resolution
Colossal’s Ben Lamm Says Invasive Species Is a $5.4 Trillion Problem. Here’s His Solution
Intellia (NASDAQ: NTLA) revises bylaws on shareholder notices and federal forums - Stock Titan
The Credibility Filter Wall Street Uses to Sort Biotech Winners
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 new Intellia employees get 67,150 stock units over 3 years - Stock Titan
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Intellia Therapeutics (NTLA) — Vanguard disaggregates holdings, parent reports 0 shares - Stock Titan
Take the Zacks Approach to Beat the Markets: LiveOne, Micron, Clorox in Focus
Take the Zacks Approach to Beat the Markets: LiveOne, Micron, Clorox in Focus
Hudson Bay Capital Management LP Sells 235,000 Shares of Intellia Therapeutics, Inc. $NTLA
Take the Zacks Approach to Beat the Markets: Starbucks, Amgen, Allogene in Focus
Cathie Wood's weekly recap: adds to AMZN, BABA, HOOD, COIN, cuts TSM, BIDU
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?
Most and least shorted small-to-mid-cap stocks
A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound